Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and Chemotherapy
| Status: | Completed |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | December 2004 |
| End Date: | July 2012 |
Monitoring Targeted Lung Cancer Treatments With FDG-PET/CT
RATIONALE: Measuring changes in glucose metabolism in patients with cancer may help doctors
predict how patients respond to treatment.
PURPOSE: This clinical trial is studying glucose metabolism in patients with non-small cell
lung cancer treated with targeted therapy and chemotherapy.
predict how patients respond to treatment.
PURPOSE: This clinical trial is studying glucose metabolism in patients with non-small cell
lung cancer treated with targeted therapy and chemotherapy.
OBJECTIVES:
- Determine the prognostic significance of changes in glucose metabolism measured by
fludeoxyglucose F 18 positron emission tomography (FDG-PET)/CT scan in patients with
non-small cell lung cancer treated with targeted drugs comprising gefitinib, erlotinib
hydrochloride, or other ErbB inhibitors, cyclooxygenase-2 inhibitors, or estrogen
receptor blockers in combination with conventional chemotherapy.
OUTLINE: This is a prospective study.
Patients undergo fludeoxyglucose F 18 positron emission tomography (FDG-PET) scan and CT
scan at baseline and at 2 weeks and 12 weeks after receiving targeted anticancer treatment.
Metabolic changes detected by FDG-PET and size changes identified by CT scan are related to
patient outcome and tumor response to treatment.
PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.
- Determine the prognostic significance of changes in glucose metabolism measured by
fludeoxyglucose F 18 positron emission tomography (FDG-PET)/CT scan in patients with
non-small cell lung cancer treated with targeted drugs comprising gefitinib, erlotinib
hydrochloride, or other ErbB inhibitors, cyclooxygenase-2 inhibitors, or estrogen
receptor blockers in combination with conventional chemotherapy.
OUTLINE: This is a prospective study.
Patients undergo fludeoxyglucose F 18 positron emission tomography (FDG-PET) scan and CT
scan at baseline and at 2 weeks and 12 weeks after receiving targeted anticancer treatment.
Metabolic changes detected by FDG-PET and size changes identified by CT scan are related to
patient outcome and tumor response to treatment.
PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.
Inclusion Criteria:
- Histologically or cytologically confirmed non-small cell lung cancer
- Any disease stage allowed
- Undergoing targeted treatment
Exclusion Criteria:
We found this trial at
1
site
10833 Le Conte Avenue # 8-950
Los Angeles, California 90095
Los Angeles, California 90095
(310) 825-5268
Jonsson Comprehensive Cancer Center at UCLA In the late 1960s, a group of scientists and...
Click here to add this to my saved trials
